PharmaFormer predicts clinical drug responses through transfer learning guided by patient derived organoid
Abstract A major challenge in effective cancer treatment is the variability of drug responses among patients. Patient-derived organoids greatly preserve the genetic and histological characteristics even the drug sensitivities of primary tumor tissues, therefore provide a compelling approach to predi...
Saved in:
| Main Authors: | Yuru Zhou, Quanhui Dai, Yanming Xu, Shuang Wu, Minzhang Cheng, Bing Zhao |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-08-01
|
| Series: | npj Precision Oncology |
| Online Access: | https://doi.org/10.1038/s41698-025-01082-6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
CordenPharma - The CDMO Partner You Need
by: David Spichiger
Published: (2025-05-01) -
PHARMA SUPPLY CHAIN RESILIENCE. A SYSTEMATIC REVIEW
by: Balázs Bence Dienes, et al.
Published: (2024-06-01) -
In vitro drug testing using patient-derived ovarian cancer organoids
by: Lin-Yu Chen, et al.
Published: (2024-10-01) -
Youth Should Be Part of African Pharma Industry—A Perspective
by: Samuel Inshutiyimana
Published: (2025-04-01) -
Correction: In vitro drug testing using patient-derived ovarian cancer organoids
by: Lin-Yu Chen, et al.
Published: (2024-12-01)